Drugs / Alovudine
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT02232581 | Apr → Dec 2004 | HIV infectious disease | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT00002260 | — | HIV infectious disease | Lederle Laboratories | Completed | No outcome recorded |
| — | NCT00002254 | — | HIV infectious disease | Lederle Laboratories | Completed | No outcome recorded |
| — | NCT00002271 | — | HIV infectious disease | Lederle Laboratories | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alovudine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00002271 ↗ |
| Known as | FLT | “An Open-Label, Crossover Study to Assess the Effect of Food on the Oral Bioavailability and Pharmacokinetic Profile of 3'-Deoxy-3'-Fluorothymidine (FLT) in Asymptomatic Human...” NCT00002260 ↗ |
| Route | Oral | “multiple oral dosing” NCT00002254 ↗ |